SCHEMBL2545867

SCHEMBL2545867

NNC(=O)C1CCC(c2cccc(Cl)n2)CC1

nearest known ligand 0.44

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
HPGD P15428 1/20 0.44
PLAU P00749 1/20 0.40
HTR1A P08908 4/20 0.38
DRD2 P14416 4/20 0.38
DRD4 P21917 4/20 0.38
ABL1 P00519 3/20 0.38
GAA P10253 1/20 0.38
ALDH1A1 P00352 1/20 0.37
ADORA3 P0DMS8 1/20 0.37
ADORA2A P29274 1/20 0.37
ADORA1 P30542 1/20 0.37
VCP P55072 1/20 0.36
SYK P43405 1/20 0.36
IDO1 P14902 1/20 0.36
KCNH2 Q12809 1/20 0.36
MEN1 O00255 1/20 0.36
KMT2A Q03164 1/20 0.36
CNR2 P34972 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2545864 1.00 HPGD (0.44) HPGDPLAUHTR1ADRD2DRD4
SCHEMBL2542224 0.83 DRD2 (0.52) HPGDHTR1ADRD2DRD4ALDH1A1
SCHEMBL2549353 0.83 HTR1A (0.51) HPGDPLAUHTR1ADRD2DRD4
SCHEMBL2542227 0.83 DRD2 (0.52) HPGDHTR1ADRD2DRD4ALDH1A1
SCHEMBL7711110 0.83 HPGD (0.44) HPGDPLAUHTR1ADRD2DRD4
SCHEMBL2549354 0.83 HTR1A (0.51) HPGDPLAUHTR1ADRD2DRD4
SCHEMBL2544294 0.82 PDE4D (0.47) HPGDGAAVCP
SCHEMBL2544291 0.82 PDE4D (0.47) HPGDGAAVCP
Bicarbonate SCHEMBL19583807 0.81 POLB (0.41) GAAALDH1A1SYKIDO1MEN1
SCHEMBL12261628 0.80 SMN1; SMN2 (0.45) HPGDHTR1ADRD2DRD4GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2560975-B1 HETEROARYL-CYCLOHEXYL-TETRAAZABENZO[E]AZULENES AS VASOPRESSIN V1A RECEPTOR ANTAGONISTS HOFFMANN LA ROCHE (CH) 2015-06-17 EP disclosed
US-8492376-B2 Heteroaryl-cyclohexyl-tetraazabenzo[e]azulenes HOFFMANN-LA ROCHE INC. (US) 2013-07-23 US disclosed
EP-2560975-A1 HETEROARYL-CYCLOHEXYL-TETRAAZABENZO[E]AZULENES AS VASOPRESSIN V1A RECEPTOR ANTAGONISTS F. Hoffmann-La Roche AG (CH) 2013-02-27 EP disclosed
WO-2011131596-A1 HETEROARYL-CYCLOHEXYL-TETRAAZABENZO[E]AZULENES AS VASOPRESSIN V1A RECEPTOR ANTAGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2011-10-27 WO disclosed
US-20110263578-A1 HETEROARYL-CYCLOHEXYL-TETRAAZABENZO[E]AZULENES HOFFMANN-LA ROCHE, INC. 2011-10-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110263578-A1 HETEROARYL-CYCLOHEXYL-TETRAAZABENZO[E]AZULENES AVPR1A, AVPR1B, OXTR HPGD 2601/4885PLAU 1578/4885HTR1A 26/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.